


PHARMACEUTICAL 2023

OMEROS CORP Rank 72 of 446









PHARMACEUTICAL 2023

OMEROS CORP Rank 72 of 446



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of OMEROS CORP is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 228%, being 185% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	443,236
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	136,383
Liabilities, Non-Current	0
Other Assets	147,733
Other Compr. Net Income	0
Other Expenses	22,702
Other Liabilities	0
Other Net Income	229,446
Other Revenues	4,062
Property and Equipment	0
Research and Development	112,721
Selling, General and Administrative Expense	50,668

Output Variable	Value in 1000 USD
Assets	590,969
Liabilities	136,383
Expenses	186,091
Revenues	4,062
Stockholders Equity	454,586
Net Income	47,417
Comprehensive Net Income	47,417
Economic Capital Ratio	228%

